516 A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

✍ Scribed by G. Weiss; R. Donehower; E. Westin; A. Bence; S. Hynes; K. Hurt

• Book ID: 119603199
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 45 KB
• Volume: 8
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(10)72223-0